Revenue Performance - Revenue for Q1 2025 was $6.8 million, a 1% increase compared to Q1 2024[6] - International revenue grew 8% in Q1 2025, now accounting for 36% of total revenue[5] - Equipment revenue for Q1 2025 was $2.1 million, up 1.4% from the previous year[6] - Average net revenue per domestic XTRAC® system increased to $4,776, a 3% year-over-year growth[6] Profitability and Loss - Gross margin improved to 53.5%, up 790 basis points from 45.6% in the prior year[6] - Adjusted EBITDA improved by $732 thousand to negative $547 thousand compared to negative $1.3 million in the prior year[6] - Net loss for Q1 2025 was $2.4 million, or EPS of negative $0.58, an improvement from a net loss of $3.4 million in Q1 2024[8] - Net loss for the three months ended March 31, 2025, was $2,432 million, an improvement from a net loss of $3,368 million in the same period of 2024[28] Operating Expenses - Operating expenses decreased by 5% to $5.7 million, with engineering & product development down 60%[8] - Cash flows from operating activities resulted in a net cash outflow of $550 million, compared to a net cash outflow of $804 million in the prior year[28] - Depreciation and amortization expenses were $1,220 million, slightly down from $1,249 million in the previous year[28] Cash and Liquidity - Total cash at the end of Q1 2025 was $7.8 million[9] - Cash, cash equivalents, and restricted cash at the end of the period totaled $7,846 million, up from $6,571 million at the end of the same period in 2024[28] - The net decrease in cash, cash equivalents, and restricted cash was $749 million, compared to a decrease of $1,547 million in the prior year[28] - Cash paid for interest during the year was $450 million, down from $480 million in the previous year[28] Inventory and Receivables - Inventory write-off was recorded at $0 million, a significant decrease from $141 million in the prior year[28] - Accounts receivable decreased by $590 million, from $726 million in 2024 to $136 million in 2025[28] Strategic Initiatives - Direct-to-consumer strategy drove 32% and 128% increases in unique Psoriasis and Acne patients, respectively[4] - The company made a purchase of property and equipment totaling $199 million, a decrease from $725 million in the same period last year[28] - Operating lease right-of-use assets obtained in exchange for operating lease were $0 million, down from $977 million in the previous year[28]
STRATA Skin Sciences(SSKN) - 2025 Q1 - Quarterly Results